alpha-synuclein genetic variability: a biomarker for dementia in parkinson disease
File(s)Guella_et al_2018+Suppl.pdf (1.04 MB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Objective
The relationship between Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB) has long been debated. Although PD is primarily considered a motor disorder, cognitive impairment is often present at diagnosis, and only ∼20% of patients remain cognitively intact in the long term. Alpha-synuclein (SNCA) was first implicated in the pathogenesis of the disease when point mutations and locus multiplications were identified in familial parkinsonism with dementia. In worldwide populations, SNCA genetic variability remains the most reproducible risk factor for idiopathic PD. However, few investigators have looked at SNCA variability in terms of cognitive outcomes.
Methods
We have used targeted high-throughput sequencing to characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB and healthy controls.
Results
An analysis of 43 tagging single nucleotide polymorphisms across the SNCA locus shows 2 distinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3′ or the 5′ of the SNCA gene. In addition, we define a specific haplotype in intron 4 that is directly associated with PDD. The PDD risk haplotype has been interrogated at single nucleotide resolution and is uniquely tagged by an expanded TTTCn repeat.
Interpretation
Our data show that PD, PDD, and DLB, rather than a disease continuum, have distinct genetic etiologies albeit within one genomic locus. Such results may serve as prognostic biomarkers to these disorders, to inform physicians and patients, and to assist in the design and stratification of clinical trials aimed at disease modification.
The relationship between Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB) has long been debated. Although PD is primarily considered a motor disorder, cognitive impairment is often present at diagnosis, and only ∼20% of patients remain cognitively intact in the long term. Alpha-synuclein (SNCA) was first implicated in the pathogenesis of the disease when point mutations and locus multiplications were identified in familial parkinsonism with dementia. In worldwide populations, SNCA genetic variability remains the most reproducible risk factor for idiopathic PD. However, few investigators have looked at SNCA variability in terms of cognitive outcomes.
Methods
We have used targeted high-throughput sequencing to characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB and healthy controls.
Results
An analysis of 43 tagging single nucleotide polymorphisms across the SNCA locus shows 2 distinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3′ or the 5′ of the SNCA gene. In addition, we define a specific haplotype in intron 4 that is directly associated with PDD. The PDD risk haplotype has been interrogated at single nucleotide resolution and is uniquely tagged by an expanded TTTCn repeat.
Interpretation
Our data show that PD, PDD, and DLB, rather than a disease continuum, have distinct genetic etiologies albeit within one genomic locus. Such results may serve as prognostic biomarkers to these disorders, to inform physicians and patients, and to assist in the design and stratification of clinical trials aimed at disease modification.
Date Issued
2016-04-18
Date Acceptance
2016-04-06
Citation
Annals of Neurology, 2016, 79 (6), pp.991-999
ISSN
0364-5134
Publisher
Wiley
Start Page
991
End Page
999
Journal / Book Title
Annals of Neurology
Volume
79
Issue
6
Copyright Statement
© 2016 American Neurological Society. This is the accepted version of the following article:Guella, I. , Evans, D. M., Szu‐Tu, C. , Nosova, E. , Bortnick, S. F., , , Goldman, J. G., Dalrymple‐Alford, J. C., Geurtsen, G. J., Litvan, I. , Ross, O. A., Middleton, L. T., Parkkinen, L. and Farrer, M. J. (2016), α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease. Ann Neurol., 79: 991-999. doi:10.1002/ana.24664, which has been published in final form at https://dx.doi.org/doi:10.1002/ana.24664
Sponsor
Parkinson's UK
Michael J Fox Foundation
Grant Number
N/A
RFA 2013
Subjects
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Neurosciences & Neurology
MESSENGER-RNA EXPRESSION
GENOME-WIDE ASSOCIATION
LEWY BODY PATHOLOGY
COGNITIVE IMPAIRMENT
DIAGNOSTIC-CRITERIA
CLINICAL-DIAGNOSIS
SNCA
BODIES
RISK
SUSCEPTIBILITY
Publication Status
Published